A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo

被引:0
作者
Nael Al Koudsi
Jasjit S Ahluwalia
Shih-Ku Lin
Edward M Sellers
Rachel F Tyndale
机构
[1] University of Toronto,Department of Pharmacology and Toxicology
[2] University of Minnesota,Department of Medicine
[3] Masonic Cancer Center,Department of Psychiatry
[4] University of Minnesota,Department of Neuroscience
[5] Taipei City Psychiatric Center,undefined
[6] Taipei City Hospital,undefined
[7] Clinical Pharmacology,undefined
[8] Kendle Early Phase,undefined
[9] Centre for Addiction and Mental Health,undefined
来源
The Pharmacogenomics Journal | 2009年 / 9卷
关键词
nicotine; cotinine; CYP2A6; smoking; pharmacogenetics;
D O I
暂无
中图分类号
学科分类号
摘要
Cytochrome P450 2A6 (CYP2A6) is the primary human enzyme involved in nicotine metabolism. The objective of this study was to characterize two nonsynonymous single nucleotide polymorphisms in CYP2A6*24, 594G>C (Val110Leu) and 6458A>T (Asn438Tyr). We determined their haplotype, allele frequencies, effect on CYP2A6 activity in vivo, as well as their stability and ability to metabolize nicotine in vitro. CYP2A6*35 (6458A>T) occurred at a frequency of 2.5–2.9% among individuals of black African descent, 0.5–0.8% among Asians and was not found in Caucasians. In addition, we identified two novel alleles, CYP2A6*36 (6458A>T and 6558T>C (Ile471Thr)) and CYP2A6*37 (6458A>T, 6558T>C and 6600G>T (Arg485Leu)). In vivo, CYP2A6*35 was associated with lower CYP2A6 activity as measured by the 3HC/COT ratio. In vitro, CYP2A6.35 had decreased nicotine C-oxidation activity and thermal stability. In conclusion, we identified three novel CYP2A6 alleles (CYP2A6*35, *36 and *37); the higher allele frequency variant CYP2A6*35 was associated with lower CYP2A6 activity.
引用
收藏
页码:274 / 282
页数:8
相关论文
共 229 条
  • [1] Benowitz NL(2008)Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction Clin Pharmacol Ther 83 531-541
  • [2] Benowitz NL(1994)Metabolism of nicotine to cotinine studied by a dual stable isotope method Clin Pharmacol Ther 56 483-493
  • [3] Jacob P(2006)Limitation of cigarette consumption by CYP2A6 Eur Respir J 27 289-292
  • [4] Minematsu N(2006)4, Clin Pharmacol Ther 79 600-608
  • [5] Nakamura H(2004)7 and Pharmacogenetics 14 615-626
  • [6] Furuuchi M(2008)9 polymorphisms Clin Pharmacol Ther 84 320-325
  • [7] Nakajima T(1996)Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation Drug Metab Dispos 24 1212-1217
  • [8] Takahashi S(1997)Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians J Pharmacol Exp Ther 282 1608-1614
  • [9] Tateno H(1996)Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion J Pharmacol Exp Ther 277 1010-1015
  • [10] Lerman C(2004)Role of human cytochrome P4502A6 in C-oxidation of nicotine Clin Pharmacol Ther 76 64-72